Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C16H17N3O5S.H2O |
Molecular Weight | 381.404 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O.[H][C@]12SCC(C)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C3=CC=C(O)C=C3)C(O)=O
InChI
InChIKey=NBFNMSULHIODTC-CYJZLJNKSA-N
InChI=1S/C16H17N3O5S.H2O/c1-7-6-25-15-11(14(22)19(15)12(7)16(23)24)18-13(21)10(17)8-2-4-9(20)5-3-8;/h2-5,10-11,15,20H,6,17H2,1H3,(H,18,21)(H,23,24);1H2/t10-,11-,15-;/m1./s1
Molecular Formula | C16H17N3O5S |
Molecular Weight | 363.388 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | H2O |
Molecular Weight | 18.0153 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Cefadroxil is a new semisynthetic cephalosporin with a broad antibacterial spectrum and a high chemotherapeutic potential when administered orally. Many studies have established the efficacy of the administration of once- or twice-daily cefadroxil in the management of infections in the respiratory tract, urinary tract, skin and soft tissues, and bones and joints.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2354204 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7447421 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | DURICEF Approved UseCefadroxil is indicated for the treatment of patients with infection caused by susceptible strains of the designated organisms in the following diseases:
Urinary tract infections caused by E. coli, P. mirabilis, and Klebsiella species.
Skin and skin structure infections caused by staphylococci and/or streptococci.
Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes (Group A beta-hemolytic streptococci). Launch Date2.56521601E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
17.9 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7073267/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
CEFADROXIL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
50.8 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7073267/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
CEFADROXIL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7073267/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
CEFADROXIL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
50 mg/kg 2 times / day steady, oral (max) Dose: 50 mg/kg, 2 times / day Route: oral Route: steady Dose: 50 mg/kg, 2 times / day Sources: |
unhealthy, 2 days -15 years n = 395 Health Status: unhealthy Condition: infections Age Group: 2 days -15 years Sex: M+F Population Size: 395 Sources: |
Other AEs: Rash, Itching... Other AEs: Rash (1.5%) Sources: Itching (1.5%) Pruritus (1.5%) Nausea (7.5%) Vomiting (7.5%) Diarrhoea (7.5%) |
50 mg/kg 2 times / day steady, oral (max) Dose: 50 mg/kg, 2 times / day Route: oral Route: steady Dose: 50 mg/kg, 2 times / day Sources: |
unhealthy, 2 days -15 years n = 366 Health Status: unhealthy Condition: infections Age Group: 2 days -15 years Sex: M+F Population Size: 366 Sources: |
Disc. AE: Diarrhoea... AEs leading to discontinuation/dose reduction: Diarrhoea (severe, 2 patients) Sources: |
15 mg/kg 2 times / day steady, oral Dose: 15 mg/kg, 2 times / day Route: oral Route: steady Dose: 15 mg/kg, 2 times / day Sources: |
unhealthy, 6 months - 12 years n = 113 Health Status: unhealthy Condition: skin infections Age Group: 6 months - 12 years Sex: M+F Population Size: 113 Sources: |
Other AEs: Vomiting... |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Itching | 1.5% | 50 mg/kg 2 times / day steady, oral (max) Dose: 50 mg/kg, 2 times / day Route: oral Route: steady Dose: 50 mg/kg, 2 times / day Sources: |
unhealthy, 2 days -15 years n = 395 Health Status: unhealthy Condition: infections Age Group: 2 days -15 years Sex: M+F Population Size: 395 Sources: |
Pruritus | 1.5% | 50 mg/kg 2 times / day steady, oral (max) Dose: 50 mg/kg, 2 times / day Route: oral Route: steady Dose: 50 mg/kg, 2 times / day Sources: |
unhealthy, 2 days -15 years n = 395 Health Status: unhealthy Condition: infections Age Group: 2 days -15 years Sex: M+F Population Size: 395 Sources: |
Rash | 1.5% | 50 mg/kg 2 times / day steady, oral (max) Dose: 50 mg/kg, 2 times / day Route: oral Route: steady Dose: 50 mg/kg, 2 times / day Sources: |
unhealthy, 2 days -15 years n = 395 Health Status: unhealthy Condition: infections Age Group: 2 days -15 years Sex: M+F Population Size: 395 Sources: |
Diarrhoea | 7.5% | 50 mg/kg 2 times / day steady, oral (max) Dose: 50 mg/kg, 2 times / day Route: oral Route: steady Dose: 50 mg/kg, 2 times / day Sources: |
unhealthy, 2 days -15 years n = 395 Health Status: unhealthy Condition: infections Age Group: 2 days -15 years Sex: M+F Population Size: 395 Sources: |
Nausea | 7.5% | 50 mg/kg 2 times / day steady, oral (max) Dose: 50 mg/kg, 2 times / day Route: oral Route: steady Dose: 50 mg/kg, 2 times / day Sources: |
unhealthy, 2 days -15 years n = 395 Health Status: unhealthy Condition: infections Age Group: 2 days -15 years Sex: M+F Population Size: 395 Sources: |
Vomiting | 7.5% | 50 mg/kg 2 times / day steady, oral (max) Dose: 50 mg/kg, 2 times / day Route: oral Route: steady Dose: 50 mg/kg, 2 times / day Sources: |
unhealthy, 2 days -15 years n = 395 Health Status: unhealthy Condition: infections Age Group: 2 days -15 years Sex: M+F Population Size: 395 Sources: |
Diarrhoea | severe, 2 patients Disc. AE |
50 mg/kg 2 times / day steady, oral (max) Dose: 50 mg/kg, 2 times / day Route: oral Route: steady Dose: 50 mg/kg, 2 times / day Sources: |
unhealthy, 2 days -15 years n = 366 Health Status: unhealthy Condition: infections Age Group: 2 days -15 years Sex: M+F Population Size: 366 Sources: |
Vomiting | 9 patients | 15 mg/kg 2 times / day steady, oral Dose: 15 mg/kg, 2 times / day Route: oral Route: steady Dose: 15 mg/kg, 2 times / day Sources: |
unhealthy, 6 months - 12 years n = 113 Health Status: unhealthy Condition: skin infections Age Group: 6 months - 12 years Sex: M+F Population Size: 113 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Retrospective analysis of drug-induced urticaria and angioedema: a survey of 2287 patients. | 2001 Nov |
|
Distribution and function of the peptide transporter PEPT2 in normal and cystic fibrosis human lung. | 2002 Jan |
|
Antibacterial activity of oral antibiotics against community-acquired respiratory pathogens from three European countries. | 2002 Jul |
|
The fecal microflora of 1-3-month-old infants during treatment with eight oral antibiotics. | 2002 Jun |
|
Intestinal transport of cefuroxime axetil in rats: absorption and hydrolysis processes. | 2002 Mar 2 |
|
PepT1 mRNA expression is induced by starvation and its level correlates with absorptive transport of cefadroxil longitudinally in the rat intestine. | 2002 Oct |
|
Uptake of cyclic dipeptide by PEPT1 in Caco-2 cells: phenolic hydroxyl group of substrate enhances affinity for PEPT1. | 2002 Sep |
|
The importance of Bi-Digital O-Ring Test in the treatment of multiple hepatic abscesses: a case history. | 2003 |
|
Unusual cause of infective discitis in an adolescent. | 2003 Apr |
|
Linezolid versus cefadroxil in the treatment of skin and skin structure infections in children. | 2003 Apr |
|
Non-hospital antimicrobial usage and resistance in community-acquired Escherichia coli urinary tract infection. | 2003 Dec |
|
An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO.SENS Project. | 2003 Jan |
|
Efficacy of cephalexin two vs. three times daily vs. cefadroxil once daily for streptococcal tonsillopharyngitis. | 2003 Jul-Aug |
|
Derivative spectrophotometry in the analysis of mixtures of cefotaxime sodium and cefadroxil monohydrate. | 2003 Jun 1 |
|
Interaction of human and rat organic anion transporter 2 with various cephalosporin antibiotics. | 2003 Mar 28 |
|
Rapid and sensitive high-performance liquid chromatographic determination of four cephalosporin antibiotics in pharmaceuticals and body fluids. | 2003 May 5 |
|
Prevalence and antimicrobial susceptibility of pathogens in uncomplicated cystitis in Europe. The ECO.SENS study. | 2003 Oct |
|
Meta-analysis of cephalosporin versus penicillin treatment of group A streptococcal tonsillopharyngitis in children. | 2004 Apr |
|
Comparison of trimethoprim-sulfamethoxazole, cephadroxil and cefprozil as prophylaxis for recurrent urinary tract infections in children. | 2004 Feb |
|
Thiolated chitosans: development and in vitro evaluation of a mucoadhesive, permeation enhancing oral drug delivery system. | 2004 Jan 8 |
|
Antimicrobial susceptibility of skin-colonizing S. aureus strains in children with atopic dermatitis. | 2004 Oct |
|
Staphylococcal skin infections in children: rational drug therapy recommendations. | 2005 |
|
PEPT2 (Slc15a2)-mediated unidirectional transport of cefadroxil from cerebrospinal fluid into choroid plexus. | 2005 Dec |
|
Heterogeneity of the IgE response to allergenic determinants of cefaclor in serum samples from patients with cefaclor-induced anaphylaxis. | 2005 Jun |
|
Bactericidal activity of oral beta-lactam antibiotics in plasma and urine versus isogenic Escherichia coli strains producing broad- and extended-spectrum beta-lactamases. | 2005 Jun |
|
Functional expression of the peptide transporter PEPT2 in the mammalian enteric nervous system. | 2005 Sep 12 |
|
A sensitive assay of amoxicillin in mouse serum and broncho-alveolar lavage fluid by liquid-liquid extraction and reversed-phase HPLC. | 2005 Sep 15 |
|
Quantitative structure/activity relationship modelling of pharmacokinetic properties using genetic algorithm-combined partial least squares method. | 2006 |
|
Positive effect of natural and negatively charged cyclodextrins on the stabilization of penicillins towards beta-lactamase degradation due to inclusion and external guest-host association. An NMR and MS study. | 2006 Apr 7 |
|
European Surveillance of Antimicrobial Consumption (ESAC): outpatient cephalosporin use in Europe. | 2006 Aug |
|
Choroid plexus epithelial monolayers--a cell culture model from porcine brain. | 2006 Dec 21 |
|
Cephalosporins can be prescribed safely for penicillin-allergic patients. | 2006 Feb |
|
Molecular interactions between dipeptides, drugs and the human intestinal H+ -oligopeptide cotransporter hPEPT1. | 2006 Jul 1 |
|
Chiral separation of cefadroxil by capillary electrochromatography. | 2006 Jun 16 |
|
Generalizability in two clinical trials of Lyme disease. | 2006 Oct 17 |
|
Species distribution and properties of staphylococci from canine dermatitis. | 2007 Feb |
|
Symptomatic relapse of group A beta-hemolytic streptococcal tonsillopharyngitis in children. | 2007 May |
|
Multi-objective optimization of an industrial penicillin V bioreactor train using non-dominated sorting genetic algorithm. | 2007 Oct 15 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/pro/cefadroxil.html
Cefadroxil tablets are acid-stable and may be administered orally without regard to meals. Administration with food may be helpful in diminishing potential gastrointestinal complaints occasionally associated with oral cephalosporin therapy.
Adults
Urinary Tract Infections
For uncomplicated lower urinary tract infections (i.e., cystitis) the usual dosage is 1 or 2 g per day in a single (q.d.) or divided doses (b.i.d.). For all other urinary tract infections the usual dosage is 2 g per day in divided doses (b.i.d.).
Skin and Skin Structure Infections
For skin and skin structure infections the usual dosage is 1 g per day in single (q.d.) or divided doses (b.i.d.).
Pharyngitis and Tonsillitis
Treatment of group A beta-hemolytic streptococcal pharyngitis and tonsillitis – 1 g per day in single (q.d.) or divided doses (b.i.d.) for 10 days.
Children
For urinary tract infections, the recommended daily dosage for children is 30 mg/kg/day in divided doses every 12 hours. For pharyngitis, tonsillitis, and impetigo, the recommended daily dosage for children is 30 mg/kg/day in a single dose or in equally divided doses every 12 hours. For other skin and skin structure infections, the recommended daily dosage is 30 mg/kg/day in equally divided doses every 12 hours. In the treatment of beta-hemolytic streptococcal infections, a therapeutic dosage of Cefadroxil tablets should be administered for at least 10 days.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/848939
Cefadroxil very effectively inhibited a broad spectrum of gram-positive and gram-negative organisms with MIC (minimal inhibitory concentration) values less than 125 ug/ml.
Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Jul 05 22:39:25 UTC 2023
by
admin
on
Wed Jul 05 22:39:25 UTC 2023
|
Record UNII |
280111G160
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C357
Created by
admin on Wed Jul 05 22:39:25 UTC 2023 , Edited by admin on Wed Jul 05 22:39:25 UTC 2023
|
||
|
WHO-VATC |
QJ01DB05
Created by
admin on Wed Jul 05 22:39:25 UTC 2023 , Edited by admin on Wed Jul 05 22:39:25 UTC 2023
|
||
|
CFR |
21 CFR 520.314
Created by
admin on Wed Jul 05 22:39:25 UTC 2023 , Edited by admin on Wed Jul 05 22:39:25 UTC 2023
|
||
|
LIVERTOX |
NBK548358
Created by
admin on Wed Jul 05 22:39:25 UTC 2023 , Edited by admin on Wed Jul 05 22:39:25 UTC 2023
|
||
|
NDF-RT |
N0000175488
Created by
admin on Wed Jul 05 22:39:25 UTC 2023 , Edited by admin on Wed Jul 05 22:39:25 UTC 2023
|
||
|
LIVERTOX |
NBK548666
Created by
admin on Wed Jul 05 22:39:25 UTC 2023 , Edited by admin on Wed Jul 05 22:39:25 UTC 2023
|
||
|
WHO-ATC |
J01DB05
Created by
admin on Wed Jul 05 22:39:25 UTC 2023 , Edited by admin on Wed Jul 05 22:39:25 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
204175
Created by
admin on Wed Jul 05 22:39:25 UTC 2023 , Edited by admin on Wed Jul 05 22:39:25 UTC 2023
|
PRIMARY | |||
|
526
Created by
admin on Wed Jul 05 22:39:25 UTC 2023 , Edited by admin on Wed Jul 05 22:39:25 UTC 2023
|
PRIMARY | |||
|
280111G160
Created by
admin on Wed Jul 05 22:39:25 UTC 2023 , Edited by admin on Wed Jul 05 22:39:25 UTC 2023
|
PRIMARY | |||
|
C28912
Created by
admin on Wed Jul 05 22:39:25 UTC 2023 , Edited by admin on Wed Jul 05 22:39:25 UTC 2023
|
PRIMARY | |||
|
D002434
Created by
admin on Wed Jul 05 22:39:25 UTC 2023 , Edited by admin on Wed Jul 05 22:39:25 UTC 2023
|
PRIMARY | |||
|
Cefadroxil
Created by
admin on Wed Jul 05 22:39:25 UTC 2023 , Edited by admin on Wed Jul 05 22:39:25 UTC 2023
|
PRIMARY | |||
|
100000092290
Created by
admin on Wed Jul 05 22:39:25 UTC 2023 , Edited by admin on Wed Jul 05 22:39:25 UTC 2023
|
PRIMARY | |||
|
53667
Created by
admin on Wed Jul 05 22:39:25 UTC 2023 , Edited by admin on Wed Jul 05 22:39:25 UTC 2023
|
PRIMARY | |||
|
M3185
Created by
admin on Wed Jul 05 22:39:25 UTC 2023 , Edited by admin on Wed Jul 05 22:39:25 UTC 2023
|
PRIMARY | Merck Index | ||
|
407888
Created by
admin on Wed Jul 05 22:39:25 UTC 2023 , Edited by admin on Wed Jul 05 22:39:25 UTC 2023
|
ALTERNATIVE | |||
|
Cefadroxil
Created by
admin on Wed Jul 05 22:39:25 UTC 2023 , Edited by admin on Wed Jul 05 22:39:25 UTC 2023
|
PRIMARY | |||
|
1097104
Created by
admin on Wed Jul 05 22:39:25 UTC 2023 , Edited by admin on Wed Jul 05 22:39:25 UTC 2023
|
PRIMARY | |||
|
CHEMBL1644
Created by
admin on Wed Jul 05 22:39:25 UTC 2023 , Edited by admin on Wed Jul 05 22:39:25 UTC 2023
|
PRIMARY | |||
|
756664
Created by
admin on Wed Jul 05 22:39:25 UTC 2023 , Edited by admin on Wed Jul 05 22:39:25 UTC 2023
|
PRIMARY | |||
|
DTXSID80904597
Created by
admin on Wed Jul 05 22:39:25 UTC 2023 , Edited by admin on Wed Jul 05 22:39:25 UTC 2023
|
PRIMARY | |||
|
66592-87-8
Created by
admin on Wed Jul 05 22:39:25 UTC 2023 , Edited by admin on Wed Jul 05 22:39:25 UTC 2023
|
PRIMARY | |||
|
280111G160
Created by
admin on Wed Jul 05 22:39:25 UTC 2023 , Edited by admin on Wed Jul 05 22:39:25 UTC 2023
|
PRIMARY | |||
|
3479
Created by
admin on Wed Jul 05 22:39:25 UTC 2023 , Edited by admin on Wed Jul 05 22:39:25 UTC 2023
|
PRIMARY | |||
|
SUB13272MIG
Created by
admin on Wed Jul 05 22:39:25 UTC 2023 , Edited by admin on Wed Jul 05 22:39:25 UTC 2023
|
PRIMARY | |||
|
DB01140
Created by
admin on Wed Jul 05 22:39:25 UTC 2023 , Edited by admin on Wed Jul 05 22:39:25 UTC 2023
|
PRIMARY | |||
|
47964
Created by
admin on Wed Jul 05 22:39:25 UTC 2023 , Edited by admin on Wed Jul 05 22:39:25 UTC 2023
|
PRIMARY | |||
|
2177
Created by
admin on Wed Jul 05 22:39:25 UTC 2023 , Edited by admin on Wed Jul 05 22:39:25 UTC 2023
|
ALTERNATIVE | |||
|
4831
Created by
admin on Wed Jul 05 22:39:25 UTC 2023 , Edited by admin on Wed Jul 05 22:39:25 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
|
||
|
ANHYDROUS->SOLVATE | |||
|
BASIS OF STRENGTH->SUBSTANCE |
calculated on the anhydrous basis
ASSAY (HPLC)
USP
|
||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
EP
|
||
|
TRANSPORTER -> INHIBITOR | |||
|
TRANSPORTER -> INHIBITOR | |||
|
BINDER->LIGAND |
BINDING
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Volume of Distribution | PHARMACOKINETIC |
|
|
|||
Biological Half-life | PHARMACOKINETIC |
|
|
|||